Spherium is a hands-on venture building, acquiring immature biomedical breakthroughs from academic institutions and de-risking them to a stage in which they can be recognized as valuable and miningful assets by the market (VC community or R&D/commercial pharma companies. We use a lean, virtual drug development model. We aim to spinout SP17001 to treat aortic aneurism, once we completed significant de-risking of the Project.